Soleil Securities Reiterates a 'Buy' on Hologic (HOLX); Continued Confidence on Tomosynthesis Launch

Soleil Securities reiterates a 'Buy' on Hologic (NASDAQ: HOLX), PT $25.

Soleil analyst says, "We continue to feel confident that Hologic's recently approved Dimensions Tomosynthesis could have a solid launch...Our FY11 Dimensions Tomosynthesis contribution = $53MM: $30MM incremental instrument sales and $23MM in software upgrades. Our FY12 Dimensions Tomosynthesis contribution = $83MM: $60MM incremental instrument sales and $23MM in software upgrades."

For more ratings news on Hologic click here and for the rating history of Hologic click here.

Shares of Hologic closed at $21.87 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Morgan Stanley Upgrades HDB Financial Services (HDBFS:IN) to Overweight
• BofA Securities Upgrades Moderna (MRNA) to Neutral
• Morgan Stanley Upgrades Suncor Energy (SU) to Overweight